Absci gains after Morgan Stanley starts with 'overweight' rating

** Shares of Absci Corp  ABSI.O  rises 7.7% to $3.2 in
premarket trading
    ** Morgan Stanley initiates coverage on the AI biologics
firm with "overweight" rating and $7 price target, implying a
more than twofold upside to last close
    ** ABSI is using its artificial intelligence and machine
learning-enabled (AI/ML) platform to reduce costs and increase
point-of-sale for antibody therapies, MS says 
    ** Collaborations with biopharma firms such as AstraZeneca
 AZN.L  in oncology and with Almirall  ALM.MC  in dermatology
validates ABSI's approach - brokerage
    ** "We see risk/reward skewed to upside at current levels
ahead of catalysts and updates that will provide significant
clarity into Absci's pipeline and platform efforts" - MS
    ** Five of six brokerages rate the stock "buy" and one
"hold"; median PT is $8 - LSEG data
    ** As of last close, ABSI down ~29% YTD vs S&P 500
Biotechnology index's  .SPLRCTKBI  ~6.4% gain during the period
    

 (Reporting by Roshan Abraham)
 ((Roshan.Abraham@thomsonreuters.com))

Recent news on AbSci

See all news